Optimization of SBRT and Intracavitary Brachytherapy for Locally Advanced Cervical Cancer

来源 :第九届泛珠江区域放射肿瘤学学术大会暨肿瘤放射治疗多中心协作研讨会、重庆市医学会放射肿瘤治疗学专业委员会2014年会 | 被引量 : 0次 | 上传用户:chrisdc
下载到本地 , 更方便阅读
声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架
论文部分内容阅读
  Objective:This work is aimed to investigate treatment planning strategies to optimally combine stereotactic body radiation therapy (SBRT) with intracavitary brachytherapy (ICBT) for the treatment of locally advanced cervical cancer.Methods: Fourteen patients (stage ⅡB-ⅢB) previously treated with combined SBRT and ICBT were randomly selected for this retrospective study.All patients were CT-and MR-scanned with a ring applicator in situ.HR-CTV and OARs were contoured according to fused CT and MR images.Several ICBT plans were generated for each patient based on different dose prescription points, and then a matching SBRT plan was generated for each ICBT plan.The dose distribution of each composite plan was analyzed with a focus on the doses received by 90% and 100% of the target volume (D90 and D1100), the target volume receiving 100% of the prescription dose (V100%), and the doses received by 2cc and 40% of the OARs (D2cc and D40).Results: As the distance between the prescription point and the tandem, d, varied between 1.0 and 1.8cm, the D90, D100 and V100% for the target, and D2cc and D40 for the bladder an rectum approached their optimal values with the d value between 1.0 and 1.3cm.Conclusions: When designing a combined ICBT+SBRT plan, one shall measure the size of the cervix and set the prescription isodose line 1.0~1.3cm away from the tandem for the ICBT plan first and then optimize the SBRT plan based on the ICBT dose distribution to achieve the best target coverage and critical structure sparin.
其他文献
目的:探讨改良的术前短程同步放化疗对局部晚期中低位直肠癌的临床近期疗效和急性放射性毒性反应.方法:中低位局部晚期直肠癌26例行改良的术前短程同步放化疗,术前放射治疗的剂量为30~39Gy,分次剂量为3Gy/d,每周5d.自放疗开始,给予5-Fu 225 mg/m2持续静脉泵入,d1~5/周.休息3~4周行手术治疗,观察临床近期疗效和毒性反应.结果:总有效率(CR+PR)为88.46%,术后病理学完
Background: Locally advanced rectal adenocarcinoma is typically treated by neoadjuvant chemo-radiotherapy and surgery.We assessed the effect of an additional cycle of capecitabine/oxaliplatin chemothe
Objective: To investigate the clinical value and application of ATP based bioluminescence tumor chemosensitivity assay(ATP-TCA) in the chemotherapy for hydrothorax caused by non-small cell lung cancer
目的:以4D-CT影像为基础探讨三维方向上胸廓动度大小与乳腺癌根治术后靶区的剂量学关系,并观察胸廓动度对心脏、肺等危及器官的剂量学影响,及靶区PTV设计.材料和方法:收集10例初治左乳腺癌根治术后患者,分别采取俯卧位及仰卧位,行4D-CT扫描并采集基础相、呼气末相、吸气末相的CT信息.分别在仰卧位与俯卧位时的基础时相上勾画CTV,然后在基础相上分别融合呼气相、吸气相图像,再勾画CTV-hu、CTV
目的:观察乳腺癌术后同期放化疗的临床应用可行性.方法:回顾性分析我院1991年12月~2003年2月行同期放化治疗的98例乳腺癌术后患者,按照RTOG评价标准,使用SPSS11.0软件、COX比例风险回归模型分析患者5、10年局部控制率、远处转移率、生存率及急性、晚期毒性反应.结果:98例经细胞学或病理学确诊的乳腺癌患者,化疗方案以标准CAF/CEF、CMF为主(21天/疗程),平均6.0疗程/例
目的:探讨印记基因PHLDA2过表达对骨肉瘤辐射敏感性的影响及相关的分子机制.方法:通过基因转染技术将真核表达质粒pEGFP-C3-PHLDA2导入骨肉瘤U2OS细胞,经G418持续筛选获得稳定高表达PHLDA2蛋白的亚克隆细胞;采用CKK8比色法测定细胞增殖活性;克隆形成实验观察细胞存活能力;Annexin V/PI染色法检测细胞凋亡;Western blot测定蛋白的表达变化;建立入骨肉瘤裸鼠
目的:探讨EGFR活化诱导的Twist-1、Bmi-1介导的EMT及肿瘤细胞干性作用与人食管鳞癌细胞株TE-1的放射敏感性的关系.方法:采用实时显微观察法探讨EGFR配体及其抑制剂作用后食管癌TE-1细胞EMT形态学特征;采用Western blots检测EGFR配体及其抑制剂作用后食管癌TE-1细胞EMT和干细胞相关标志Twist-1、Bmi-1蛋白表达水平;采用克隆形成法研究抑制EGFR活化和
目的:研究神经生长因子(nerve growth factor,NGF)和E-钙粘蛋白(E-cadherin,E-CD)在肝细胞肝癌(以下简称肝癌)中的表达,及其与肝癌复发转移的关系.方法:采用免疫组化方法检测45例肝癌组织和对应的癌旁硬化肝组织,以及15例肝血管瘤旁肝组织(对照组)手术切除标本的NGF及E-CD的表达情况.结果:肝癌组织中NGF与E-CD的阳性率分别为68.9%与40.0%.NG
目的:分析初治NSCLC患者肺原发灶EGFR (epidermal growth factor receptor, EGFR)基因突变状态与临床病理特征的相关性,为临床EGFR-TKIs (tyrosine kdnase inhibitors,TKIs)用药提供依据.方法:收集2011年7月至2013年5月第三军医大学附属大坪医院应用增殖阻遏突变系统(amplification refractor
目的:探讨非小细胞肺癌(Non-small cell lung cancer, NSCLC)发生脑转移对肺原发灶EGFR基因突变的预测作用.方法:通过显微镜观察EGFR基因19外显子缺失突变型HCC827和EGFR基因野生型A549人肺腺癌细胞形态学差异,应用MTT法检测HCC827和A549细胞增殖差异,采用Transwell细胞体外侵袭实验比较两株细胞侵袭能力的强弱.并应用x2检验分析253例